Pharma Pulse 4/17/24: At-Home Patients and AI, Psychedelics Present Unique Ethical Challenges & more


The latest news for pharma industry insiders.

At-Home Patients and AI

Riccardo Butta discusses how new technologies are being implemented in at-home devices.

Psychedelics Present Unique Ethical Challenges

In an interview with Pharmacy Times, Sa’ed Al-Olimat, PharmD, co-founder of the Psychedelic Pharmacists Association, discussed the future of psychedelic medicines and the unique ethical challenges they present. He also discussed the roles pharmacists will play in these treatments.

AI Has a Measurement Problem

Which AI system writes the best computer code or generates the most realistic image? Right now, there’s no easy way to answer those questions.

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics

Precision BioSciences, Inc., an advanced gene editing company, announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company. Precision exercised its option to regain rights for the programs following Prevail Therapeutics’ decision to conclude the collaboration.

@UBCPharma on X:

When you design your patient services program, are you analyzing your patients' environmental hurdles or just their demographics? Learn how to address patient social determinants of health in the latest white paper form UBC at:

#PatientsFirst #SDOH

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs

© 2024 MJH Life Sciences

All rights reserved.